Pharmacovigilance reports
06/08/2026
Report No. 6: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Download PDF here
10/07/2025
Report No. 5: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Download PDF here
06/11/2024
Report No. 4: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Marketing Authorization Holder (MAH): ALEFCutoff date: September 30, 2024Download PDF here
03/05/2023
Report No. 3: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Download PDF here
02/05/2023
Report No. 2: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Marketing Authorization Holder (MAH): ALEFPharmacovigilance TeamDate: December 2022Download PDF here
01/05/2023
Report No. 1: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Marketing Authorization Holder (MAH): Alef Medical Argentina S.A.Pharmacovigilance Team / IPRAT S.A.Date: April 1, 2022Download...